China Pharma Holdings, Inc. (CPHI) Stock Price & Analysis
China Pharma Holdings, Inc. (CPHI) fell 17.84% to USD 1.52 as of July 25, 2026 at 05:57 UTC, according to Nexqual real-time market data.
CPHI last closed at USD 1.85; the session ranged USD 1.51–1.8 on volume of 3,477,456 shares. Market capitalization is $61.59M, with a 52-week range of USD 0.38–19.19 (ASE). Source: Nexqual, July 25, 2026 at 05:57 UTC.
Key Statistics (as of July 25, 2026 at 05:57 UTC)
| Price | USD 1.52 |
|---|---|
| Change | ▼ 17.84% (down) |
| Previous Close | USD 1.85 |
| Open | USD 1.78 |
| Day Range | USD 1.51 – 1.8 |
| 52-Week Range | USD 0.38 – 19.19 |
| Volume | 3,477,456 shares |
| Market Cap | $61.59M |
| Exchange | ASE |
Technical Analysis (CPHI)
Nexqual's technical model rates CPHI "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 05:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.6 (neutral) |
| vs SMA50 | Above (USD 0.98) |
| MACD | 0.45 (positive) |
Analyst Ratings (CPHI)
Wall Street analysts rate CPHI "None", per Nexqual as of July 25, 2026 at 05:57 UTC.
| Consensus Rating | None |
|---|
Earnings (CPHI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2011-09-30 | USD 40 vs est 60 ▼ miss |
| 2011-03-31 | USD 50 vs est 57.5 ▼ miss |
| 2010-12-31 | USD 95 vs est 78.33 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
Financials & Fundamentals (CPHI)
| Total Revenue | $3.99M |
|---|---|
| Revenue Growth (YoY) | -13.40% |
| Gross Margin | +7.26% |
| Operating Margin | -113.60% |
| Profit Margin | -88.82% |
| ROE | -16.12% |
| Debt / Equity | 10.42 |
| Current Ratio | 0.28 |
| Total Cash | $168,474 |
| Total Debt | $3.86M |
| Free Cash Flow | $1.03M |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
Financial Health Score (CPHI)
Nexqual rates China Pharma Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:57 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $168K cash vs $4M debt |
| Cash Flow | Mixed — FCF $1M, slim 1.4% margin |
| Efficiency | Critical — ROE -16%, ROA -7.3% |
Ownership (CPHI)
| Insider Ownership | +89.63% |
|---|---|
| Institutional Ownership | +0.06% |
| Shares Outstanding | 40.52M |
| Float | 800,715 |
| Short % of Float | +0.09% |
Source: Nexqual, July 25, 2026 at 05:57 UTC.
Leadership (CPHI)
China Pharma Holdings, Inc. is led by Zhilin Li (age 72), President, CEO, Chairman & Interim CFO, per Nexqual as of July 25, 2026 at 05:57 UTC.
| President, CEO, Chairman & Interim CFO | Zhilin Li (age 72) |
|---|
From China Pharma Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
- The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
- In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
- It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SXTC | China SXT Pharmaceuticals, Inc. | USD 0.06 | ▼ 96.84% |
| CREG | Smart Powerr Corp. | USD 0.77 | ▲ 354.12% |
| ZNB | Zeta Network Group | USD 0.28 | ▼ 6.67% |
| BIMI | BIMI International Medical Inc. | USD 0 | ▲ 0% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:57 UTC. This page is informational and not investment advice.